Kenney Susan, Vistica David T, Stockwin Luke H, Burkett Sandra, Hollingshead Melinda G, Borgel Suzanne D, Butcher Donna O, Schrump David S, Shoemaker Robert H
Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
J Pediatr Hematol Oncol. 2011 Jul;33(5):360-8. doi: 10.1097/MPH.0b013e3182002f9f.
In vitro growth of alveolar soft part sarcoma (ASPS) and establishment of an ASPS cell line, ASPS-1, are described in this study. Using a recently developed xenograft model of ASPS derived from a lymph node metastasis, organoid nests consisting of 15 to 25 ASPS cells were isolated from ASPS xenograft tumors by capture on 70 μm filters and plated in vitro. After attachment to the substratum, these nests deposited small aggregates of ASPS cells. These cells grew slowly and were expanded over a period of 3 years and have maintained characteristics consistent with those of both the original ASPS tumor from the patient and the xenograft tumor including (1) presence of the alveolar soft part locus-transcription factor E3 type 1 fusion transcript and nuclear expression of the alveolar soft part locus-transcription factor E3 type 1 fusion protein; (2) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS; and (3) expression of upregulated ASPS transcripts involved in angiogenesis (ANGPTL2, HIF-1-α, MDK, c-MET, VEGF, and TIMP-2), cell proliferation (PRL, PCSK1), metastasis (ADAM9), as well as the transcription factor BHLHB3 and the muscle-specific transcripts TRIM63 and ITGβ1BP3. This ASPS cell line forms colonies in soft agar and retains the ability to produce highly vascularized ASPS tumors in NOD.SCID/NCr mice. Immunohistochemistry of selected ASPS markers on these tumors indicated similarity to those of the original patient tumor as well as to the xenografted ASPS tumor. We anticipate that this ASPS cell line will accelerate investigations into the biology of ASPS including identification of new therapeutic approaches for treatment of this slow growing soft tissue sarcoma.
本研究描述了肺泡软组织肉瘤(ASPS)的体外生长及ASPS细胞系ASPS-1的建立。利用最近开发的源自淋巴结转移的ASPS异种移植模型,通过70μm滤器捕获从ASPS异种移植瘤中分离出由15至25个ASPS细胞组成的类器官巢,并进行体外接种。附着于基质后,这些巢状结构沉积出ASPS细胞的小聚集体。这些细胞生长缓慢,经过3年得以扩增,并保持了与患者原ASPS肿瘤及异种移植瘤一致的特征,包括:(1)存在肺泡软组织位点转录因子E3型1融合转录本及肺泡软组织位点转录因子E3型1融合蛋白的核表达;(2)维持ASPS特有的t(X;17)(p11;q25)易位特征;(3)表达参与血管生成(血管生成素样蛋白2、低氧诱导因子-1α、Midkine、c-Met、血管内皮生长因子和基质金属蛋白酶组织抑制因子2)、细胞增殖(催乳素、前蛋白转化酶枯草溶菌素1)、转移(解整合素金属蛋白酶9)的上调ASPS转录本,以及转录因子BHLHB3和肌肉特异性转录本TRIM63和整合素β1结合蛋白3。该ASPS细胞系在软琼脂中形成集落,并保留在NOD.SCID/NCr小鼠中产生高度血管化ASPS肿瘤的能力。对这些肿瘤上选定的ASPS标志物进行免疫组织化学分析表明,其与原患者肿瘤及异种移植的ASPS肿瘤相似。我们预计,该ASPS细胞系将加速对ASPS生物学的研究,包括确定治疗这种生长缓慢的软组织肉瘤的新治疗方法。